Erectile Dysfunction and Ischaemic Heart Disease
Author(s) -
Abdalla Ibrahim,
Mohamed Ali,
Thomas J. Kiernan,
Austin G. Stack
Publication year - 2018
Publication title -
european cardiology review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 12
eISSN - 1758-3764
pISSN - 1758-3756
DOI - 10.15420/ecr.2017.21.3
Subject(s) - medicine , erectile dysfunction , endothelial dysfunction , disease , diabetes mellitus , cgmp specific phosphodiesterase type 5 , cardiology , pathological , heart disease , stroke (engine) , type 2 diabetes , risk factor , intensive care medicine , endocrinology , mechanical engineering , engineering
Erectile dysfunction (ED) is a common disorder that affects the quality of life of many patients. It is prevalent in more than half of males aged over 60 years. Increasing evidence suggests that ED is predominantly a vascular disorder. Endothelial dysfunction seems to be the common pathological process causing ED. Many common risk factors for atherosclerosis such as diabetes, hypertension, smoking, obesity and hyperlipidaemia are prevalent in patients with ED and so management of these common cardiovascular risk factors can potentially prevent ED. Phosphodiesterase type 5 inhibitors provide short-term change of haemodynamic factors to help initiate and maintain penile erection. They have been shown to be an effective and safe treatment strategy for ED in patients with heart disease, including those with ischaemic heart disease and hypertension.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom